We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Beckman Coulter Receives Accreditation from College of American Pathologists

Rectangle Image
News

Beckman Coulter Receives Accreditation from College of American Pathologists

Read time:
 

Beckman Coulter Genomics announces accreditation from the College of American Pathologists (CAP). 

Furthering a long-standing commitment to delivering state-of-the-art sequencing services and high levels of customer satisfaction, the facility in Danvers completed a comprehensive on-site inspection as part of the CAP’s Accreditation Programs.  The CAP Laboratory Accreditation Program involves a process of inspections of clinical lab records and quality control procedures and assessments of a lab's staff qualifications, equipment, facilities, safety program, and overall management.

“Beckman Coulter Genomics is proud to achieve accreditation from the College of American Pathologists,” said Tim Anderson, vice president and general manager of genomic services. “CAP accreditation is recognized as the ‘high-water mark’ for laboratory testing. I congratulate the entire team at Beckman Coulter Genomics. This accomplishment underscores our commitment to advancing healthcare for every person and reinforces our determination to deliver the highest standards of excellence.”

Award of this respected accreditation strengthens Beckman Coulter Genomics’ already strong bioinformatics expertise and extensive experience in study design, guidance and analysis of customer’s crucial clinical samples.

“CAP accreditation signifies that our lab operates under rigorous quality standards to generate highly accurate and reliable data,” said Dr. Stephen Lyle, laboratory director at Beckman Coulter Genomics. “We are pleased to be able to provide our customers a sequencing service which satisfies the exacting requirements of regulatory authorities and will help the facility more quickly move findings from clinical trials into clinical use."

Advertisement